Statements (83)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
modulates immune response
inhibits angiogenesis immune modulation angiogenesis inhibition direct anti-tumor activity |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:can_be_used_with |
gptkb:bortezomib
gptkb:lenalidomide gptkb:dexamethasone |
| gptkbp:class |
immunomodulatory drug
|
| gptkbp:clinical_trial |
gptkb:refractory_multiple_myeloma
Phase II Phase III relapsed multiple myeloma |
| gptkbp:contraindication |
pregnancy
breastfeeding severe renal impairment |
| gptkbp:dosage_form |
gptkb:beer
4 mg once daily |
| gptkbp:effective_date |
gptkb:2013
2013-02-08 |
| gptkbp:formulation |
gptkb:beer
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pomalyst
|
| gptkbp:ingredients |
gptkb:pomalidomide
C13 H13 N3 O4 S |
| gptkbp:interacts_with |
gptkb:lenalidomide
gptkb:thalidomide gptkb:warfarin gptkb:dexamethasone antibiotics other immunosuppressants |
| gptkbp:invention |
2027
2027-02-08 |
| gptkbp:is_atype_of |
L01 X X32
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
treatment of multiple myeloma |
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Celgene_Corporation
gptkb:Celgene |
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:population |
adults
|
| gptkbp:safety_features |
renal function
liver function blood counts |
| gptkbp:side_effect |
gptkb:fandom
dizziness fatigue headache muscle pain nausea fever swelling vomiting confusion seizures diarrhea rash joint pain insomnia skin reactions constipation dry mouth chills shortness of breath peripheral neuropathy blood clots thrombocytopenia hyperkalemia increased risk of infection hypophosphatemia vision changes liver function abnormalities hypomagnesemia |
| gptkbp:storage |
room temperature
store at room temperature protect from moisture |
| gptkbp:type_of |
191732-72-6
|
| gptkbp:bfsParent |
gptkb:Celgene_Corporation
|
| gptkbp:bfsLayer |
3
|